

Alexander J Lepak

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2059454/alexander-j-lepak-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

734
citations

15
h-index

26
g-index

40
ext. papers

917
ext. citations

6.2
avg, IF

4.63
L-index

#	Paper	IF	Citations
40	Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S73-S73	1	78
39	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1265-72	5.9	73
38	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 6390-6400	3.4	57
37	Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	53
36	Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	51
35	Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	45
34	Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	38
33	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	36
32	In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 4764-9	5.9	34
31	Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	32
30	In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1258-64	5.9	28
29	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against in an Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	26
28	Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	25
27	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	19
26	Viral Sequencing to Investigate Sources of SARS-CoV-2 Infection in US Healthcare Personnel. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1329-e1336	11.6	16
25	Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	15
24	Antifungal PK/PD considerations in fungal pulmonary infections. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011 , 32, 783-94	3.9	13

23	WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo- β -lactamase producing in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 ,	5.9	13
22	Association of Changes in Seasonal Respiratory Virus Activity and Ambulatory Antibiotic Prescriptions With the COVID-19 Pandemic. <i>JAMA Internal Medicine</i> , 2021 , 181, 1399-1402	11.5	10
21	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	9
20	Determination of Pharmacodynamic Target Exposures for Rezafungin against <i>Candida tropicalis</i> and <i>Candida dubliniensis</i> in the Neutropenic Mouse Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	8
19	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3023-3028	5.1	7
18	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	7
17	Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	6
16	Pharmacodynamic Evaluation of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	6
15	In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 93, 258-260	2.9	6
14	Implementation of infection control measures to prevent healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2). <i>Infection Control and Hospital Epidemiology</i> , 2021 , 42, 229-232	2	5
13	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 65,	5.9	4
12	Pharmacodynamic Target Determination for Delafloxacin against <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	3
11	COVID-19 in Health Care Personnel: Significance of Health Care Role, Contact History, and Symptoms in Those Who Test Positive for SARS-CoV-2 Infection. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2312-2322	6.4	3
10	Utility of Repeat Nasopharyngeal SARS-CoV-2 RT-PCR Testing and Refinement of Diagnostic Stewardship Strategies at a Tertiary Care Academic Center in a Low-Prevalence Area of the United States. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa388	1	2
9	The Wrong Frame of Mind. <i>New England Journal of Medicine</i> , 2018 , 378, 1716-1721	59.2	1
8	Isavuconazole: Has It Saved Us? A Pharmacotherapy Review and Update on Clinical Experience. <i>Current Treatment Options in Infectious Diseases</i> , 2017 , 9, 356-370	1	1
7	Clinical utility of dual anterior nares and oropharynx MRSA screening polymerase chain reaction assay (PCR) for patients with suspected pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 1-3	2	1
6	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	1

5	Viral sequencing reveals US healthcare personnel rarely become infected with SARS-CoV-2 through patient contact		1
4	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against <i>S. aureus</i> (SA) and <i>S. pneumoniae</i> (SPN). <i>Open Forum Infectious Diseases</i> , 2018 , 5, S426-S426	1	1
3	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 2256-2264	2.2	0
2	Letter to the Editor. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1548		11.6
1	Clinical Utility of Dual Anterior Nares and Oropharynx MRSA Screening PCR for Patients with Suspected Pneumonia - ERRATUM.. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 1		2